Covering all the bases: Preclinical development of an effective staphylococcus aureus vaccine

Frontiers in Immunology

Volumn 5, Issue MAR, 2014, Pages

  Scully, Ingrid L ^a   Liberator, Paul A ^a   Jansen, Kathrin U ^a   Anderson, Annaliesa S ^a  

^a Pfizer Vaccine Research and Development Unit   (United States)

Author keywords

Capsular polysaccharide conjugates; Clumping factor A; Immunoassays; Manganese transport protein C; Preclinical models; Staphylococcus aureus; Vaccine

Indexed keywords

MANGANESE; PNEUMOCOCCUS VACCINE; REACTIVE OXYGEN METABOLITE; STAPHYLOCOCCUS VACCINE; SUPEROXIDE DISMUTASE; VIRULENCE FACTOR;

ANIMAL MODEL; DRUG DESIGN; DRUG EFFICACY; HUMAN; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOASSAY; NEUTROPHIL; PATHOGENESIS; PHAGOCYTOSIS; REVIEW; STAPHYLOCOCCUS AUREUS;

EID: 84897935824     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00109     Document Type: Review

References (77)

1. Malachowa N, Whitney AR, Kobayashi SD, Sturdevant DE, Kennedy AD, Braughton KR, et al. Global changes in Staphylococcus aureus gene expression in human blood. PLoS One (2011) 6(4):e18617. doi:10.1371/journal.pone.0018617
2. Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev (1997) 10(3):505-20.
3. Lowy FD. Staphylococcus aureus infections. N Engl J Med (1998) 339(8):520-32. doi:10.1056/NEJM199808203390806
4. Noskin GA, Rubin RJ, Schentag JJ, Kluytmans J, Hedblom EC, Jacobson C, et al. National trends in Staphylococcus aureus infection rates: impact on economic burden and mortality over a 6-year period (1998-2003). Clin Infect Dis (2007) 45(9):1132-40. doi:10.1086/522186
5. Torres VJ, Pishchany G, Humayun M, Schneewind O, Skaar EP. Staphylococcus aureus IsdB is a hemoglobin receptor required for heme iron utilization. J Bacteriol (2006) 188(24):8421-9. doi:10.1128/JB.01335-06
6. Horsburgh MJ, Wharton SJ, Cox AG, Ingham E, Peacock S, Foster SJ. MntR modulates expression of the PerR regulon and superoxide resistance in Staphylococcus aureus through control of manganese uptake. Mol Microbiol (2002) 44(5):1269-86. doi:10.1046/j.1365-2958.2002.02944.x
7. Jonsson K, Signas C, Muller HP, Lindberg M. Two different genes encode fibronectin binding proteins in Staphylococcus aureus. The complete nucleotide sequence and characterization of the second gene. Eur J Biochem (1991) 202(3):1041-8. doi:10.1111/j.1432-1033.1991.tb16468.x
8. Massey RC, Kantzanou MN, Fowler T, Day NP, Schofield K, Wann ER, et al. Fibronectin-binding protein A of Staphylococcus aureus has multiple, substituting, binding regions that mediate adherence to fibronectin and invasion of endothelial cells. Cell Microbiol (2001) 3(12):839-51. doi:10.1046/j.1462-5822.2001.00157.x
9. McDevitt D, Nanavaty T, House-Pompeo K, Bell E, Turner N, McIntire L, et al. Characterization of the interaction between the Staphylococcus aureus clumping factor (ClfA) and fibrinogen. Eur J Biochem (1997) 247(1):416-24. doi:10.1111/j.1432-1033.1997.00416.x
10. Ni Eidhin D, Perkins S, Francois P, Vaudaux P, Hook M, Foster TJ. Clumping factor B (ClfB), a new surface-located fibrinogen-binding adhesin of Staphylococcus aureus. Mol Microbiol (1998) 30(2):245-57. doi:10.1046/j.1365-2958.1998.01050.x
11. Patti JM, Jonsson H, Guss B, Switalski LM, Wiberg K, Lindberg M, et al. Molecular characterization and expression of a gene encoding a Staphylococcus aureus collagen adhesin. J Biol Chem (1992) 267(7):4766-72.
12. Nanra JS, Buitrago SM, Crawford S, Ng J, Fink PS, Hawkins J, et al. Capsular polysaccharides are an important immune evasion mechanism for Staphylococcus aureus. Hum Vaccin Immunother (2012) 9(3):480-7. doi:10.4161/hv.23223
13. Smith EJ, Visai L, Kerrigan SW, Speziale P, Foster TJ. The Sbi protein is a multifunctional immune evasion factor of Staphylococcus aureus. Infect Immun (2011) 79(9):3801-9. doi:10.1128/IAI.05075-11
14. Rooijakkers SH, Ruyken M, Roos A, Daha MR, Presanis JS, Sim RB, et al. Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases. Nat Immunol (2005) 6(9):920-7. doi:10.1038/ni1235
15. Forsgren A, Sjoquist J. "Protein A" from S. aureus. I. Pseudo-immune reaction with human gamma-globulin. J Immunol (1966) 97(6):822-7.
16. Bhakdi S, Tranum-Jensen J. Alpha-toxin of Staphylococcus aureus. Microbiol Rev (1991) 55(4):733-51.
17. Choi YW, Kotzin B, Herron L, Callahan J, Marrack P, Kappler J. Interaction of Staphylococcus aureus toxin "superantigens" with human T cells. Proc Natl Acad Sci U S A (1989) 86(22):8941-5. doi:10.1073/pnas.86.22.8941
18. Genestier AL, Michallet MC, Prevost G, Bellot G, Chalabreysse L, Peyrol S, et al. Staphylococcus aureus Panton-Valentine leukocidin directly targets mitochondria and induces Bax-independent apoptosis of human neutrophils. J Clin Invest (2005) 115(11):3117-27. doi:10.1172/JCI22684
19. Hawkins J, Kodali S, Matsuka YV, McNeil LK, Mininni T, Scully IL, et al. A recombinant clumping factor A-containing vaccine induces functional antibodies to Staphylococcus aureus that are not observed after natural exposure. Clin Vaccine Immunol (2012) 19(10):1641-50. doi:10.1128/CVI.00354-12
20. Verdrengh M, Tarkowski A. Role of neutrophils in experimental septicemia and septic arthritis induced by Staphylococcus aureus. Infect Immun (1997) 65(7):2517-21.
21. Rigby KM, DeLeo FR. Neutrophils in innate host defense against Staphylococcus aureus infections. Semin Immunopathol (2012) 34(2):237-59. doi:10.1007/s00281-011-0295-3
22. DeLeo FR, Diep BA, Otto M. Host defense and pathogenesis in Staphylococcus aureus infections. Infect Dis Clin North Am (2009) 23(1):17-34. doi:10.1016/j.idc.2008.10.003
23. von Aulock S, Morath S, Hareng L, Knapp S, van Kessel KP, van Strijp JA, et al. Lipoteichoic acid from Staphylococcus aureus is a potent stimulus for neutrophil recruitment. Immunobiology (2003) 208(4):413-22. doi:10.1078/0171-2985-00285
24. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol (2003) 21:335-76. doi:10.1146/annurev.immunol.21.120601.141126
25. Foster TJ. Immune evasion by staphylococci. Nat Rev Microbiol (2005) 3(12):948-58. doi:10.1038/nrmicro1289
26. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med (1966) 64(2):328-40. doi:10.7326/0003-4819-64-2-328
27. Quie PG, White JG, Holmes B, Good RA. In vitro bactericidal capacity of human polymorphonuclear leukocytes: diminished activity in chronic granulomatous disease of childhood. J Clin Invest (1967) 46(4):668-79. doi:10.1172/JCI105568
28. Johnston RB Jr, Keele BB Jr, Misra HP, Lehmeyer JE, Webb LS, Baehner RL, et al. The role of superoxide anion generation in phagocytic bactericidal activity. Studies with normal and chronic granulomatous disease leukocytes. J Clin Invest (1975) 55(6):1357-72. doi:10.1172/JCI108055
29. Heyworth PG, Cross AR, Curnutte JT. Chronic granulomatous disease. Curr Opin Immunol (2003) 15(5):578-84. doi:10.1016/S0952-7915(03)00109-2
30. Dinauer MC. Disorders of neutrophil function: an overview. Methods Mol Biol (2007) 412:489-504. doi:10.1007/978-1-59745-467-4_30
31. Lorenz E, Mira JP, Cornish KL, Arbour NC, Schwartz DA. A novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect Immun (2000) 68(11):6398-401. doi:10.1128/IAI.68.11.6398-6401.2000
32. Figueroa JE, Densen P. Infectious diseases associated with complement deficiencies. Clin Microbiol Rev (1991) 4(3):359-95.
33. de Beaucoudrey L, Puel A, Filipe-Santos O, Cobat A, Ghandil P, Chrabieh M, et al. Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. J Exp Med (2008) 205(7):1543-50. doi:10.1084/jem.20080321
34. Ma CS, Chew GY, Simpson N, Priyadarshi A, Wong M, Grimbacher B, et al. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med (2008) 205(7):1551-7. doi:10.1084/jem.20080218
35. Milner JD, Brenchley JM, Laurence A, Freeman AF, Hill BJ, Elias KM, et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature (2008) 452(7188):773-6. doi:10.1038/nature06764
36. Jacobson MA, Gellermann H, Chambers H. Staphylococcus aureus bacteremia and recurrent staphylococcal infection in patients with acquired immunodeficiency syndrome and AIDS-related complex. Am J Med (1988) 85(2):172-6. doi:10.1016/S0002-9343(88)80337-1
37. Maraqa NF, Aigbivbalu L, Masnita-Iusan C, Wludyka P, Shareef Z, Bailey C, et al. Prevalence of and risk factors for methicillin-resistant Staphylococcus aureus colonization and infection among infants at a level III neonatal intensive care unit. Am J Infect Control (2011) 39(1):35-41. doi:10.1016/j.ajic.2010.07.013
38. Mickenberg ID, Root RK, Wolff SM. Leukocytic function in hypogammaglobulinemia. J Clin Invest (1970) 49(8):1528-38. doi:10.1172/JCI106370
39. Trakultivakorn M, Ochs HD. X-linked agammaglobulinemia in northern Thailand. Asian Pac J Allergy Immunol (2006) 24(1):57-63.
40. Fauci A. Harrison's Principles of Internal Medicine. 14th ed. New York: McGraw-Hill Companies (1998).
41. Lin L, Ibrahim AS, Xu X, Farber JM, Avanesian V, Baquir B, et al. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog (2009) 5(12):e1000703. doi:10.1371/journal.ppat.1000703
42. Anderson AS, Miller AA, Donald RG, Scully IL, Nanra JS, Cooper D, et al. Development of a multicomponent Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors. Hum Vaccin Immunother (2012) 8(11):1585-94. doi:10.4161/hv.21872
43. Thakker M, Park JS, Carey V, Lee JC. Staphylococcus aureus serotype 5 capsular polysaccharide is antiphagocytic and enhances bacterial virulence in a murine bacteremia model. Infect Immun (1998) 66(11):5183-9.
44. Shinefield H, Black S, Fattom A, Horwith G, Rasgon S, Ordonez J, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med (2002) 346(7):491-6. doi:10.1056/NEJMoa011297
45. Matalon AM, Buerkert J, Block G, Hohenboken M, Fattom A, Horwirth G, et al. Efficacy profile of a bivalent Staphylococcus aureus glycoconjugate investigational vaccine in adults on haemodialysis: phase III randomized study. International Symposium on Staphylococci and Staphylococcal Infections. Lyon (2012).
46. Eskola J, Peltola H, Takala AK, Kayhty H, Hakulinen M, Karanko V, et al. Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in infancy. N Engl J Med (1987) 317(12):717-22. doi:10.1056/NEJM198709173171201
47. Paradiso PR, Hogerman DA, Madore DV, Keyserling H, King J, Reisinger KS, et al. Safety and immunogenicity of a combined diphtheria, tetanus, pertussis and Haemophilus influenzae type b vaccine in young infants. Pediatrics (1993) 92(6):827-32.
48. Ramsay ME, Andrews N, Kaczmarski EB, Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet (2001) 357(9251):195-6. doi:10.1016/S0140-6736(00)03594-7
49. Peltola H, Makela H, Kayhty H, Jousimies H, Herva E, Hallstrom K, et al. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl J Med (1977) 297(13):686-91. doi:10.1056/NEJM197709292971302
50. Keyserling H, Papa T, Koranyi K, Ryall R, Bassily E, Bybel MJ, et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med (2005) 159(10):907-13. doi:10.1001/archpedi.159.10.907
51. Shinefield HR, Black S. Efficacy of pneumococcal conjugate vaccines in large scale field trials. Pediatr Infect Dis J (2000) 19(4):394-7. doi:10.1097/00006454-200004000-00036
52. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J (2000) 19(3):187-95. doi:10.1097/00006454-200003000-00003
53. Harro C, Betts R, Orenstein W, Kwak EJ, Greenberg HE, Onorato MT, et al. Safety and immunogenicity of a novel Staphylococcus aureus vaccine: results from the first study of the vaccine dose range in humans. Clin Vaccine Immunol (2010) 17(12):1868-74. doi:10.1128/CVI.00356-10
54. Zorman JK, Esser M, Raedler M, Kreiswirth BN, Ala'Aldeen DA, Kartsonis N, et al. Naturally occurring IgG antibody levels to the Staphylococcus aureus protein IsdB in humans. Hum Vaccin Immunother (2013) 9(9):1857-64. doi:10.4161/hv.25253
55. Fowler VG, Allen K, Moreira E, Moustafa M, Isgro F, Boucher H, et al. Efficacy and Safety of an Investigational Staphylococcus aureus Vaccine in Preventing Bacteremia and Deep Sternal Wound Infections after Cardiothoracic Surgery. San Diego, CA: IDWeek (2012).
56. Kim HK, DeDent A, Cheng AG, McAdow M, Bagnoli F, Missiakas DM, et al. IsdA and IsdB antibodies protect mice against Staphylococcus aureus abscess formation and lethal challenge. Vaccine (2010) 28(38):6382-92. doi:10.1016/j.vaccine.2010.02.097
57. Brown M, Kowalski R, Zorman J, Wang XM, Towne V, Zhao Q, et al. Selection and characterization of murine monoclonal antibodies to Staphylococcus aureus iron-regulated surface determinant B with functional activity in vitro and in vivo. Clin Vaccine Immunol (2009) 16(8):1095-104. doi:10.1128/CVI.00085-09
58. Ebert T, Smith S, Pancari G, Clark D, Hampton R, Secore S, et al. A fully human monoclonal antibody to Staphylococcus aureus iron regulated surface determinant B (IsdB) with functional activity in vitro and in vivo. Hum Antibodies (2010) 19(4):113-28. doi:10.3233/HAB-2010-0235
59. Anderson AS, Scully IL, Timofeyeva Y, Murphy E, McNeil LK, Mininni T, et al. Staphylococcus aureus manganese transport protein C is a highly conserved cell surface protein that elicits protective immunity against S. aureus and Staphylococcus epidermidis. J Infect Dis (2012) 205(11):1688-96. doi:10.1093/infdis/jis272
60. Kuklin NA, Clark DJ, Secore S, Cook J, Cope LD, McNeely T, et al. A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect Immun (2006) 74(4):2215-23. doi:10.1128/IAI.74.4.2215-2223.2006
61. Bagnoli F, Bertholet S, Grandi G. Inferring reasons for the failure of Staphylococcus aureus vaccines in clinical trials. Front Cell Infect Microbiol (2012) 2:16. doi:10.3389/fcimb.2012.00016
62. Stranger-Jones YK, Bae T, Schneewind O. Vaccine assembly from surface proteins of Staphylococcus aureus. Proc Natl Acad Sci U S A (2006) 103(45):16942-7. doi:10.1073/pnas.0606863103
63. McDevitt D, Francois P, Vaudaux P, Foster TJ. Identification of the ligand-binding domain of the surface-located fibrinogen receptor (clumping factor) of Staphylococcus aureus. Mol Microbiol (1995) 16(5):895-907. doi:10.1111/j.1365-2958.1995.tb02316.x
64. O'Brien L, Kerrigan SW, Kaw G, Hogan M, Penades J, Litt D, et al. Multiple mechanisms for the activation of human platelet aggregation by Staphylococcus aureus: roles for the clumping factors ClfA and ClfB, the serine-aspartate repeat protein SdrE and protein A. Mol Microbiol (2002) 44(4):1033-44. doi:10.1046/j.1365-2958.2002.02935.x
65. McAdow M, Kim HK, Dedent AC, Hendrickx AP, Schneewind O, Missiakas DM. Preventing Staphylococcus aureus sepsis through the inhibition of its agglutination in blood. PLoS Pathog (2011) 7(10):e1002307. doi:10.1371/journal.ppat.1002307
66. Josefsson E, Hartford O, O'Brien L, Patti JM, Foster T. Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. J Infect Dis (2001) 184(12):1572-80. doi:10.1086/324430
67. Moreillon P, Entenza JM, Francioli P, McDevitt D, Foster TJ, Francois P, et al. Role of Staphylococcus aureus coagulase and clumping factor in pathogenesis of experimental endocarditis. Infect Immun (1995) 63(12):4738-43.
68. Handke LD, Hawkins JC, Miller AA, Jansen KU, Anderson AS. Regulation of Staphylococcus aureus MntC expression and its role in response to oxidative stress. PLoS One (2013) 8(10):e77874. doi:10.1371/journal.pone.0077874
69. Brady RA, O'May GA, Leid JG, Prior ML, Costerton JW, Shirtliff ME. Resolution of Staphylococcus aureus biofilm infection using vaccination and antibiotic treatment. Infect Immun (2011) 79(4):1797-803. doi:10.1128/IAI.00451-10
70. den Reijer PM, Lemmens-den Toom N, Kant S, Snijders SV, Boelens H, Tavakol M, et al. Characterization of the humoral immune response during Staphylococcus aureus bacteremia and global gene expression by Staphylococcus aureus in human blood. PLoS One (2013) 8(1):e53391. doi:10.1371/journal.pone.0053391
71. Lowell GH, Kaminski RW, Grate S, Hunt RE, Charney C, Zimmer S, et al. Intranasal and intramuscular proteosome-staphylococcal enterotoxin B (SEB) toxoid vaccines: immunogenicity and efficacy against lethal SEB intoxication in mice. Infect Immun (1996) 64(5):1706-13.
72. Brown EL, Dumitrescu O, Thomas D, Badiou C, Koers EM, Choudhury P, et al. The Panton-Valentine leukocidin vaccine protects mice against lung and skin infections caused by Staphylococcus aureus USA300. Clin Microbiol Infect (2009) 15(2):156-64. doi:10.1111/j.1469-0691.2008.02648.x
73. Hu DL, Omoe K, Sasaki S, Sashinami H, Sakuraba H, Yokomizo Y, et al. Vaccination with nontoxic mutant toxic shock syndrome toxin 1 protects against Staphylococcus aureus infection. J Infect Dis (2003) 188(5):743-52. doi:10.1086/377308
74. Neill RJ, Fanning GR, Delahoz F, Wolff R, Gemski P. Oligonucleotide probes for detection and differentiation of Staphylococcus aureus strains containing genes for enterotoxins A, B, and C and toxic shock syndrome toxin 1. J Clin Microbiol (1990) 28(7):1514-8.
75. Lina G, Piemont Y, Godail-Gamot F, Bes M, Peter MO, Gauduchon V, et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis (1999) 29(5):1128-32. doi:10.1086/313461
76. Foletti D, Strop P, Shaughnessy L, Hasa-Moreno A, Casas MG, Russell M, et al. Mechanism of action and in vivo efficacy of a human-derived antibody against Staphylococcus aureus alpha-hemolysin. J Mol Biol (2013) 425(10):1641-54. doi:10.1016/j.jmb.2013.02.008
77. Hua L, Hilliard JJ, Shi Y, Tkaczyk C, Cheng LI, Yu X, et al. Assessment of an anti-alpha toxin mAb for prevention and treatment of Staphylococcus aureus induced pneumonia. Antimicrob Agents Chemother (2013). doi:10.1128/AAC.02190-13